WaveMan
WaveMan · Company
LUCY · Innovative Eyewear Inc
> Search tickers & screens ⌘K
LIVE
← All companies

LUCY Innovative Eyewear (LUCY) Insider Trading, Ownership & Congress Trades

Medical Devices · Ophthalmic goods · CIK 0001808377
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

What the filings say about LUCY

Insiders, 180 days
-$29.6K net sold
5 sellers · 0% of sales under a 10b5-1 plan

Innovative Eyewear insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Innovative Eyewear Inc insiders sold a net $29.6K of stock across 108 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Gayle Oswald
Chief Financial Officer
SELL
2026-08-24 SECtraded 2026-08-19
7,959
$5.4K
-19.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Apr 2, 2026.
  • The trade is 40.2% of the 19,798 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gayle Oswald sold about $5.4K of LUCY on Aug 19, 2026; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Dabrowski Konrad
Chief AI & Growth Officer
SELL
2026-08-24 SECtraded 2026-08-19
6,935
$4.8K
-19.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Apr 2, 2026.
  • The trade is 16.9% of the 40,977 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief AI & Growth Officer Dabrowski Konrad sold about $4.8K of LUCY on Aug 19, 2026; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Abondano Joaquin
Chief Operating Officer
SELL
2026-08-24 SECtraded 2026-08-19
5,020
$3.4K
-19.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 2, 2026.
  • The trade is 20.1% of the 25,012 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Abondano Joaquin sold about $3.4K of LUCY on Aug 19, 2026; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Gross Harrison R.
Chief Executive Officer
SELL
2026-08-24 SECtraded 2026-08-19
8,252
$5.7K
-19.0%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (3 buys, 5 sales), the last on Apr 2, 2026.
  • -23.9% median (+6.4% mean) 90-day return after 3 previous buys.
  • The trade is 20.2% of the 40,917 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Gross Harrison R. sold about $5.7K of LUCY on Aug 19, 2026; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Gross Harrison R.
Chief Executive Officer
SELL
2026-08-24 SECtraded 2026-08-19
5,722
$4.0K
-19.0%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (3 buys, 5 sales), the last on Apr 2, 2026.
  • -23.9% median (+6.4% mean) 90-day return after 3 previous buys.
  • The trade is 16.3% of the 35,195 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Gross Harrison R. sold about $4.0K of LUCY on Aug 19, 2026; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
108 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 103 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$29.6K over 180 days
-$27.5K over 90 days
more than 59% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Medical Devices
Revenue
+62.6% year over year
more than 89% of Medical Devices
Margin
-285.2% net margin
below 88% of Medical Devices
Buybacks
no share repurchases reported
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 58% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LUCY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-52.1%12M
-64%-42%-20%+2%2025-102025-122026-022026-042026-062026-082026-10 2026-01-07 · Galkin Vladimir bought $1.2M2025-12-26 · Galkin Vladimir bought $110.7K2025-12-31 · Galkin Vladimir bought $88.9K2025-12-10 · Galkin Vladimir bought $74.9K2025-12-29 · Galkin Vladimir bought $50.7K2025-12-23 · Galkin Vladimir bought $43.8K2026-04-02 · Gross Harrison R. sold $14.7K2025-12-11 · Galkin Vladimir bought $13.3K2025-12-30 · Galkin Vladimir bought $12.2K2025-12-18 · Galkin Vladimir bought $10.5K2026-04-02 · Gayle Oswald sold $8.1K2025-12-17 · Galkin Vladimir bought $7.4K2026-04-02 · Dabrowski Konrad sold $7.1K2025-12-19 · Galkin Vladimir bought $6.6K2026-04-02 · Cohen David Eric sold $6.2K2026-08-19 · Gross Harrison R. sold $5.7K2026-08-19 · Gayle Oswald sold $5.4K2026-04-02 · Abondano Joaquin sold $5.0K2026-08-19 · Dabrowski Konrad sold $4.8K2026-08-19 · Cohen David Eric sold $4.2K2026-01-02 · Galkin Vladimir bought $4.1K2026-08-19 · Gross Harrison R. sold $4.0K2025-12-04 · Galkin Vladimir bought $3.8K2026-08-19 · Abondano Joaquin sold $3.4K2026-01-08 · Gross Harrison R. bought $2.4K2026-07-06 · Cohen David Eric sold $2.2K2026-04-09 · Cohen David Eric sold $2.1K2026-01-08 · Dabrowski Konrad bought $2.1K2026-01-21 · Gross Harrison R. bought $2.0K2026-01-02 · Galkin Vladimir bought $1.2K2025-12-24 · Galkin Vladimir bought $1.2K2026-01-13 · Gayle Oswald bought $1.2K2026-01-13 · Gayle Oswald bought $5072025-12-22 · Galkin Vladimir bought $4952026-07-06 · Cohen David Eric filed to sell $2.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LUCY: institutional holders (13F)

13F holdings, latest reported quarter
Cetera Investment Advisers
577,350 sh
$450.3K
XTX Topco Ltd
40,996 sh
$32.0K
CITADEL ADVISORS LLC
57,801 sh
$24.6K
KEYBANK NATIONAL ASSOCIATION/OH
20,000 sh
$15.6K
GEODE CAPITAL MANAGEMENT, LLC
18,135 sh
$14.1K

Congress trades in LUCY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LUCY planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Cohen David Eric
Filed 2026-07-06
$2.1K
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $29.6K sold by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

LUCY financials

Revenue growth
+62.6%
XBRL, annual
Net margin
-285.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.0M
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
-272.5%
net income over revenue, 2025-04-01 to 2026-03-31
Free cash flow, TTM
-$7.5M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-102.4%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets
-93.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-135.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.7M$1.6M$1.2M$659.8K
Gross profit$567.5K$215.2K-$119.3K-$56.3K
Net income-$7.6M-$7.8M-$6.7M-$5.7M
EPS (diluted)-1.90-5.19-10.87-0.87
Operating cash flow-$7.3M-$6.7M-$5.8M-$3.2M
Cash$6.5M$2.6M$4.3M$3.6M
SEC XBRL, fiscal years, as known on 2026-10-27

LUCY Stock Sonar score 5/7 axes

Find similar shapesCompare

LUCY ranks highest on growth (89th percentile) and risk and compliance (81st), and lowest on institutional and government (14th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
22
Inputs
  • Return on equity-102.4% · 25 pct, sector of 183
  • Return on assets-93.2% · 20 pct, sector of 214
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Growth
89
Inputs
  • Revenue growth, YoY+62.6% · 89 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
29
Inputs
  • Net Form 4 buying (codes P and S), 180d-$30K · 58 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
14
Inputs
  • Funds adding, latest quarter9 · 14 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
81
Inputs
  • Short interest, % of float+2.2% · 69 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.1% · 93 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LUCY filings, in plain words

Are Innovative Eyewear insiders buying or selling LUCY?

In the 180 days to 2026-10-27, Innovative Eyewear insiders were net sellers, a net $29.6K across purchases and sales reported on Form 4, by 5 sellers.

Read the full summary

In the 180 days to 2026-10-27, Innovative Eyewear insiders were net sellers of LUCY, a net $29.6K across purchases and sales reported on Form 4 by 5 sellers. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies